Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alvespimycin + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of alvespimycin (17-DMAG), a second-generation Heat Shock Protein 90 (Hsp90) inhibitor, and trastuzumab (Herceptin), a monoclonal antibody targeting HER2. This combination has been studied for the treatment of HER2-positive metastatic breast cancer and other solid tumors, showing antitumor activity in patients with refractory disease.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)HSP90 (Heat shock protein 90 chaperone complex)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on alvespimycin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alvespimycin + trastuzumab.